Economy/Home · Economy

[Breaking] Samick Pharmaceutical Hits Upper Limit... Soars 29.95% to 8,330 Won, Standing Out in KOSDAQ's 4%-Plus Rally

Samick Pharmaceutical (014950) surged to its daily price limit during the morning session on the 10th. Even amid a strong market where both the KOSPI and KOSDAQ indices rose together, Samick Pharmaceutical's sharp rally stood out conspicuously, drawing keen attention from investors. As of 10:32 a.m

Oseong Kwon
Staff Reporter
3 min read
[Breaking] Samick Pharmaceutical Hits Upper Limit... Soars 29.95% to 8,330 Won, Standing Out in KOSDAQ's 4%-Plus Rally
CBC News

Samick Pharmaceutical (014950) surged to its daily price limit during the morning session on the 10th. Even amid a strong market where both the KOSPI and KOSDAQ indices rose together, Samick Pharmaceutical's sharp rally stood out conspicuously, drawing keen attention from investors.

As of 10:32 a.m. on the 10th, Samick Pharmaceutical was trading on the KOSDAQ market at 8,330 won, up 1,920 won (29.95%) from the previous trading day. The stock recorded a clear gain from early in the session, breaking above the 8,000-won level, and whether it can hold the upper limit until the close emerged as a key point to watch.

At the same time, the broader domestic stock market was also maintaining strength. The KOSPI index stood at 5,211.81, up 192.96 points (3.84%) from the previous trading day, while the KOSDAQ index rose 26.90 points (4.20%) to 665.87. With both indices climbing in tandem, Samick Pharmaceutical was moving well above the KOSDAQ market's overall gain.

Attention now turns to whether the current rise can be sustained through the afternoon session, and what trajectory the stock will follow after this sharp surge.

[※ This article is for investment reference purposes only, and investment decisions and their consequences are the responsibility of the individual investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.